Current Controversies in Oncology

Current Controversies in Oncology and Current Insights in Oncology articles provide a forum for the exchange of views on topical issues in the field of oncology. The opinions expressed are those of the authors alone. They do not necessarily reflect the views of the Editor or ASCO.

Dec 14, 2014
"As you can surmise from the articles by Dr. Mark Moyad and Dr. L. Michael Glodé, one thing we can say with certainty is that dietary supplements are mired in controversy."
Oct 24, 2014
"Induction chemotherapy may theoretically enhance treatment outcomes  . . . by decreasing tumor volume, and therefore the fraction of hypoxic cells that contribute to radioresistance; by bringing about chemosensitization, particularly in combination with platins and . . ."
Aug 26, 2014
"There is overwhelming evidence that RARP is associated with decreased blood loss, lower transfusion rates, and shorter length of hospital stay."
Jun 19, 2014
"Another major advantage of PET is its ability to detect distant metastasis in organs outside the central nervous system when CT is negative."
Apr 22, 2014
"As oncologists, we painstakingly translate clinical evidence for our patients. We inform them of odds, percentages, risks, and survival. When it comes to deciding on a treatment path, we lean heavily on the potential of physical toxicity, as we should, but are we missing . . ."
Feb 25, 2014
"The availability of more effective combination chemotherapy regimens is transformative and potentially lays the foundation for greater benefit with chemoradiation. We need to figure this out."
Dec 16, 2013
"Given the possibility of using highly effective anti-androgen treatment . . . with new agents and the promise hinted at by sipuleucel-T and fowlpox-PSA-TRICOM vaccine, it should be possible to contemplate cure of metastatic prostate cancer within the next decade."
Oct 28, 2013
"The big question is whether adjuvant chemotherapy can improve the chanceof cure in resected stage II colon cancer.The beneficial role of adjuvant chemotherapy has been clearly demonstrated in stage III colon cancer.However, evidence in stage II colon cancer . . ."
Aug 22, 2013
"The majority of patients with thyroid cancer have low-risk disease. There is wide hospital-based variation in radioactive iodine use for low-risk disease, suggesting that in some instances there may be overuse . . ."
Jun 25, 2013
"Unfortunately, the urologic oncology community has yet to identify barriers to the use of neoadjuvant chemotherapy that can be overcome in a widespread fashion. In some centers such as ours, we have adopted the practice of referring all patients with T2 or higher tumor . . ."